In 2017, there was a breakthrough, and several new drugs, including venetoclax and selective B cell lymphoma-2 (BCL-2) inhibitors, seemed to reshape the therapeutic landscape of AML (2). Here, BCL2 is linked to acute myeloid leukemia.